Condition
Locally advanced or unresectable PIK3CA and/or PTENaltered metaplastic or non-metaplastic triple negative breast cancer.
Total Trials
1
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Eribulin
Related Conditions
Often studied with 4 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Active Not Recruiting1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Eribulin1
- Men16111
Active Sponsors
- MedSIR1
- Menarini Group1
- Medica Scientia Innovation Research S.L.1
Top Investigators
Arnau de Vilanova Hospital, Valencia (Spain)
Institute of Breast Cancer, Quirón Group, Barcelona (Spain)
Related Conditions
- Breast Cancer1
- Advanced Breast Cancer1
- Locally Advanced Or Unresectable Pik3ca Andor Ptenaltered Metaplastic Hrpositiveher2negative Breast Cancer1
- Metastatic Breast Cancer1